What it does
Weight LossCardiovascular HealthBlood Sugar ControlAppetite SuppressionT2D Management
Semaglutide is the benchmark GLP-1 agonist. It is the most studied and the best-tolerated entry point for members new to GLP-1 therapy. Effects build gradually with titration. Most members notice significant appetite reduction by week 4-6. Strong cardiovascular data sets it apart from newer compounds with less published evidence. Pairs exceptionally well with Cagrilintide, which is the combination currently in Phase 3 clinical trials as CagriSema.
Reconstitution
Mixing Instructions
1
Add 2mL bacteriostatic water to your 5mg vial.
2
Inject slowly down the glass wall.
3
Gently swirl until clear. Do not shake.
4
Label with date. Refrigerate. For best results, use within 28 days of reconstitution.
Dosing Reference
Based on standard reconstitution above. All doses subcutaneous unless noted.
| Dose | Syringe (units) | Volume (mL) |
|---|---|---|
| 0.25mg | 10 units | 0.1mL |
| 0.5mg | 20 units | 0.2mL |
| 1mg | 40 units | 0.4mL |
| 1.7mg | 68 units | 0.68mL |
| 2.4mg | 96 units | 0.96mL |
Protocol
Research Protocol
Weeks 1-40.25mg per week
Weeks 5-80.5mg per week
Weeks 9-121mg per week
Weeks 13+1.7-2.4mg per week based on tolerance
RouteSubcutaneous
CycleOngoing - commonly used long-term
Split doseRecommended - divide weekly dose Mon/Thu
All BodhiPep compounds are for research use only. For educational purposes only.